ParAllele inks licensing deal for genotyping tech

ParAllele BioScience has inked a deal with Merck to use its genotyping technology to track the genetic variations that influence a person's susceptibility to cancer and their response to therapeutics. No financial terms were disclosed. "Merck has pioneered the application of genetics to cancer, and we are excited about this opportunity to broaden our collaborative relationship," said Hywel B. Jones, PhD, ParAllele's senior director of business development. "Our high-throughput technologies allow the determination of changes in copy number in tumors in a very efficient manner."

- read this press release for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.